Daily aspirin could reduce colorectal cancer risk in LS patients, says NICE

The National Institution of Health and Care Excellence (NICE) has advised in new draft updated guidance that taking aspirin daily for two or more years could reduce the risk of colorectal cancer in people with Lunch syndrome (LS).

When published, the updated guideline will replace NICE’s existing guideline on the diagnosis and management of colorectal cancer.

An estimated 175,000 people in the UK have LS, a large proportion of whom will be unaware that they have the condition.

People with LS have an increased lifetime risk – estimated to be four out of five people – of developing colorectal cancer.

Regular screening with colonoscopy and polypectomy to identify pre-cancerous cells has until now been the main strategy to detect early colorectal cancer in people with LS and offer appropriate management.

“The independent committee looked at evidence from a multi-country randomised controlled trial, which showed taking daily aspirin for more than two years reduces the risk of colorectal cancer in people with Lynch syndrome,” said Dr Paul Chrisp, Director of the Centre for Guidelines at NICE.

“While there are risks associated with long-term aspirin use, the committee agreed that the benefits are likely to outweigh any potential harms.

“It is important that clinicians and patients discuss the potential harms and benefits of long-term aspirin use so that an informed decision can be made.”

NICE published diagnostics guidance in 2017 recommending that everyone who is diagnosed with colorectal cancer should be tested for LS.

If the test shows they do have LS, they can be monitored for other cancers and their close relatives can also be offered testing for LS.

Updated guidance recommends aspirin is an option to reduce the risk of colorectal cancer among this group.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Related news

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...